DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01599338

CompletedPhase NA

Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients

Influence du Victoza (Liraglutide,Analogue GLP-1) Sur Les Performances Gustatives, le Rassasiement Sensoriel spécifique, le Liking et le Wanting Chez Les Patients diabétiques de Type 2.

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

30

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

•BMI ≥25

Primary endpoints

•Liking and wanting for protein, lipid and glucid foods•Sensory specific satiety for protein, lipid and glucid foods•Gustative detection thresholds for sweet, bitter and salty tastes

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01599338
Org study IDA100991-10
Secondary ID2010-022618-19

Timeline

Milestones

Study first posted2012-05-16estimated
Last update posted2012-06-01estimated
Study start2011-01 (month precision)
Primary completion2011-01actual (month precision)
Study completion2011-09actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

Type 2 diabetic patients

1. with glycemic unbalance despite anti-diabetic treatments and

2. overweight (BMI > 25 kg/m²)

Exclusion criteria

•Impaired renal function (creatinine clearance < 50 ml/min),
•Pregnancy,
•Congestive heart failure,
•Acute and chronic infection,
•Evolutive cancer,
•Cirrhosis,
•Ongoing antibiotic treatment,
•Smoking (more than 5 cig/day),
•Alcohol consumption (more than 20 g/day),
•Aversion for the foods eaten or smelt during the study,
•Impaired comprehension for cognitive tasks,
•Treatments known to interfere with olfactory and gustative performances

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
3
Weight & body composition
1
Patient-reported / QoL
1
Other (unclassified)
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Change in body mass composition (Dual Energy XRay Absorptiometry)

Time frame:3 months

change from baseline, improvement

Patient-reported / QoL

1 endpoint
Primary/protocol endpoint

Change in appetite, desire to eat, pleasure in eating

Time frame:3 months

change from baseline, improvement

Other clinical outcomes

3 endpoints
Primary/protocol endpoint/low confidence

Change in liking and wanting for protein, lipid and glucid foods

Time frame:3 months

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change in sensory specific satiety for protein, lipid and glucid foods

Time frame:3 months

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change in gustative detection thresholds for sweet, bitter and salty tastes

Time frame:3 months

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Change in plasma ghrelin, leptin, and HbA1c levels

Time frame:3 months

change from baseline, improvement

componentsLeptin, change, HbA1c, change

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.